hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06350396, orgStudyIdInfo id: CPLTRDDM2024, briefTitle: pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Changping Laboratory, class: OTHER, descriptionModule briefSummary: This study is a multicenter, randomized, double-blind, placebo-controlled trial aimed at exploring the effectiveness and safety of rTMS intervention with DMPFC targets guided by pBFS in patients with treatment-resistant depression., conditionsModule conditions: Treatment Resistant Depression, conditions: Major Depressive Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 270, type: ESTIMATED, armsInterventionsModule interventions name: active rTMS treatment, interventions name: sham rTMS treatment, outcomesModule primaryOutcomes measure: Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline to Immediate Post-treatment, secondaryOutcomes measure: Remission and response rates were estimated using Montgomery-Asberg Depression Rating Scale(MADRS), secondaryOutcomes measure: Remission and response rates were estimated using Hamilton Depression Rating Scale (HAMD-17), secondaryOutcomes measure: Changes in the MADRS from baseline to each visit, secondaryOutcomes measure: Changes in the HAMD-17 from baseline to each visit, secondaryOutcomes measure: cognitive change in Digit Symbol Substitution Test (DSST), secondaryOutcomes measure: cognitive change in continuous performance test (CPT), secondaryOutcomes measure: cognitive change in Trail-Making Test (TMT), secondaryOutcomes measure: cognitive change in Digit Span Test (DST), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hebei Mental Health Center, city: Hebei, state: Baoding, country: China, contacts name: Lili Zhang, role: CONTACT, locations facility: West China Hospital, Sichuan University, city: Chengdu, country: China, contacts name: Qiyong Gong, role: CONTACT, geoPoint lat: 30.66667, lon: 104.06667, locations facility: Inner Mongolia Mental Health Center, city: Hohhot, country: China, contacts name: Dongsheng Lv, role: CONTACT, geoPoint lat: 40.81056, lon: 111.65222, locations facility: Shandong Daizhuang Hospital, city: Jining, country: China, contacts name: Zhonggang Wang, role: CONTACT, geoPoint lat: 35.405, lon: 116.58139, locations facility: The Second Affiliated Hospital of Xinxiang Medical University, city: Xinxiang, country: China, contacts name: Yongfeng Yang, role: CONTACT, geoPoint lat: 35.19033, lon: 113.80151, hasResults: False
protocolSection identificationModule nctId: NCT06350370, orgStudyIdInfo id: NCC3489, briefTitle: Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-01-01, primaryCompletionDateStruct date: 2023-01-01, completionDateStruct date: 2028-01-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, class: OTHER, descriptionModule briefSummary: Natural orifice specimen extraction surgery (NOSES) has gained widespread recognition among scholars and has gradually been promoted and popularized around the world. However, the development of NOSES is still in the exploratory stage and there is a lack of strong evidence from evidence-based medicine to support its feasibility and safety, which has greatly affected its clinical application and development. Based on this, at the call of Professor Xishan Wang, the Chinese NOSES Alliance conducted a large retrospective clinical study involving multiple centers. By summarizing the NOSES cases of nearly 100 centers in China, the study aims to clarify the current status of NOSES surgery in China. Additionally, a comprehensive analysis and summary was conducted by combining the basic information of NOSES patients, perioperative data, postoperative pathological data, and follow-up information to further demonstrate the safety and feasibility of NOSES in the treatment of colorectal cancer. This study also provides more real and objective evidence-based medicine support for the promotion and development of NOSES surgery., conditionsModule conditions: Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8000, type: ESTIMATED, armsInterventionsModule interventions name: Natural orifice specimen extraction, outcomesModule primaryOutcomes measure: Rate of short-term complication, secondaryOutcomes measure: Operative duration, secondaryOutcomes measure: Intraoperative blood loss, secondaryOutcomes measure: Time to first flatus after surgery, secondaryOutcomes measure: Time to first stool after surgery, secondaryOutcomes measure: Length of stay after surgery, secondaryOutcomes measure: 3-year disease free survival, secondaryOutcomes measure: 3-year overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital Chinese Academy of Medical Sciences, status: RECRUITING, city: Beijing, state: Beijing, zip: 100021, country: China, contacts name: Xishan Wang, role: CONTACT, phone: 13261967603, email: wxshan_cams@163.com, contacts name: Mingguang Zhang, role: CONTACT, phone: +8613261967603, email: zmgslimshady@163.com, contacts name: Xishan Wang, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06350357, orgStudyIdInfo id: 2024B014, briefTitle: Conventional Clipping Versus Punching Closure, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Ningbo No. 1 Hospital, class: OTHER, descriptionModule briefSummary: Endoscopic submucosal dissection (ESD) is an important minimally invasive treatment method for early digestive tract tumors, with a high cure rate, and it is widely used in clinical practice. And wound closure after ESD is a great challenge, which is closely related to postoperative perforation bleeding. Clip closure is one of the most commonly used closure methods. However, when the wound is large or when the wound is located more difficult to operate, conventional closure may lead to delayed perforation, and postoperative clips may be prone to early spontaneous shedding. The authors have recently reported a method that may be able to close larger and difficult wounds because the grooves can better fix the metal clips. The latest study suggests that this approach may be safe and effective, but the study has a small sample size and has no controls. Therefore, high-quality clinical study evidence related to punch closure is required in the strategy of defect closure after ESD, in order to better evaluate the feasibility and safety of this new endoscopic closure method., conditionsModule conditions: the Rate of Complete Closure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: punching closure, interventions name: Conventional clipping, outcomesModule primaryOutcomes measure: Completely closed, secondaryOutcomes measure: delayed hemorrhage, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ningbo first hospital, status: RECRUITING, city: Ningbo, state: Zhejiang, country: China, contacts name: Lei Xu, role: CONTACT, phone: +86-13486659126, email: xulei22@163.com, geoPoint lat: 29.87819, lon: 121.54945, hasResults: False
protocolSection identificationModule nctId: NCT06350344, orgStudyIdInfo id: HZKY-PJ-2024-8-2, briefTitle: Smart Technology Facilitated Patient-centered Venous Thromboembolism Management, acronym: SmaVTE-COR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-11-01, primaryCompletionDateStruct date: 2026-10-31, completionDateStruct date: 2027-10-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Navy General Hospital, Beijing, class: OTHER, descriptionModule briefSummary: Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE., conditionsModule conditions: Venous Thromboembolism, conditions: Digital Health, conditions: Health Education, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 2353, type: ESTIMATED, armsInterventionsModule interventions name: mobile venous thromboembolism application (mVTEA), outcomesModule primaryOutcomes measure: VTE-related composite event, secondaryOutcomes measure: VTE-KAP questionnaire score, secondaryOutcomes measure: Generic quality of life, secondaryOutcomes measure: VTE events, secondaryOutcomes measure: Major bleeding, secondaryOutcomes measure: VTE-related hospitalization, secondaryOutcomes measure: New-onset of atrial fibrillation or atrial flutter, secondaryOutcomes measure: Death, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sixth Medical Center of Chinese PLA General Hospital, city: Beijing, state: Beijing, zip: 100048, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06350331, orgStudyIdInfo id: HZKY-PJ-2024-8-1, briefTitle: Smart Technology Facilitated Patient-centered Venous Thromboembolism Management, acronym: SmaVTE-RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Navy General Hospital, Beijing, class: OTHER, descriptionModule briefSummary: Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on patients' perceptions of thromboprophylaxis, in order to enhance clinical practice and establish a foundation of evidence for managing patients with VTE., conditionsModule conditions: Venous Thromboembolism, conditions: Digital Health, conditions: Health Education, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 256, type: ESTIMATED, armsInterventionsModule interventions name: mobile venous thromboembolism application (mVTEA), outcomesModule primaryOutcomes measure: VTE-KAP questionnaire score, secondaryOutcomes measure: Knowledge, attitude, and practice scores in the VTE-KAP questionnaire, secondaryOutcomes measure: Generic quality of life, secondaryOutcomes measure: VTE events, secondaryOutcomes measure: Chronic thromboembolic pulmonary hypertension (CTEPH), secondaryOutcomes measure: Chronic thromboembolic pulmonary disease (CTEPD), secondaryOutcomes measure: Post-pulmonary embolism syndrome (PPES), secondaryOutcomes measure: Major bleeding, secondaryOutcomes measure: VTE-related hospitalization, secondaryOutcomes measure: VTE-related rehospitalization, secondaryOutcomes measure: New-onset of atrial fibrillation or atrial flutter, secondaryOutcomes measure: Death, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sixth Medical Center of Chinese PLA General Hospital, city: Beijing, state: Beijing, zip: 100048, country: China, contacts name: ZHI-GENG JIN, Doctor, role: CONTACT, phone: 8615801402223, email: lwgjzg@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06350318, orgStudyIdInfo id: MCC-22005, briefTitle: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2029-03, completionDateStruct date: 2029-03, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: H. Lee Moffitt Cancer Center and Research Institute, class: OTHER, collaborators name: BeiGene, Ltd., descriptionModule briefSummary: The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas)., conditionsModule conditions: Follicular Lymphoma, conditions: Marginal Zone Lymphoma, conditions: B-Cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 43, type: ESTIMATED, armsInterventionsModule interventions name: Zanubrutinib, interventions name: Rituximab, outcomesModule primaryOutcomes measure: Overall Response Rate: Cohort A, primaryOutcomes measure: Overall Response Rate: Cohort B, secondaryOutcomes measure: Efficacy of Zanubrutinib and Rituximab, secondaryOutcomes measure: Safety and tolerability of combination Zanubrutinib and Rituximab, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Moffitt Cancer Center, status: RECRUITING, city: Tampa, state: Florida, zip: 33612, country: United States, contacts name: Richard Corona, role: CONTACT, phone: 813-745-3465, email: Richard.Corona@moffitt.org, contacts name: Sameh Gaballa, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 27.94752, lon: -82.45843, hasResults: False
protocolSection identificationModule nctId: NCT06350305, orgStudyIdInfo id: Screening for high-risk COPD, briefTitle: Screening for High-risk Chronic Obstructive Pulmonary Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-04-30, completionDateStruct date: 2027-10-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Henan University of Traditional Chinese Medicine, class: OTHER, descriptionModule briefSummary: This study is a multicenter cross-sectional study design aimed at screening risk factors for the combination of disease and syndrome in high-risk individuals with chronic obstructive pulmonary disease (COPD)., conditionsModule conditions: High-risk COPD, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 3600, type: ESTIMATED, armsInterventionsModule interventions name: questionnaire survey, outcomesModule primaryOutcomes measure: COPD screening questionnaire from Terrassa (EGARPOC), primaryOutcomes measure: COPD assessment in primary care to identify undiagnosed respiratory disease and exacerbation risk questionnaire (CAPTURE), primaryOutcomes measure: COPD Assessment Test (CAT), primaryOutcomes measure: COPD screening questionnaire (COPD-Q), primaryOutcomes measure: chronic obstructive pulmonary disease diagnostic questionnaire (CDQ), primaryOutcomes measure: modified chronic obstructive pulmonary disease diagnostic questionnaire (mCDQ), primaryOutcomes measure: Simple screening questionnaire, primaryOutcomes measure: lung function questionnaire (LFQ), primaryOutcomes measure: chronic obstructive pulmonary disease screening questionnaire (COPD-SQ), primaryOutcomes measure: chronic obstructive pulmonary disease population screener questionnaire (COPD-PS), primaryOutcomes measure: Chronic Obstructive Pulmonary Disease Risk Scale (COPDRS), primaryOutcomes measure: Standardised Scale of Physical Fitness in Chinese Medicine, primaryOutcomes measure: Syndrome therapeutic evaluation scale of chronic obstructive pulmonary disease (COPD-STES), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Henan University of Chinese Medicine, city: Zhengzhou, state: Henan, zip: 450000, country: China, contacts name: yang Xie, doctor, role: CONTACT, phone: 0371-66248624, email: xieyanghn@163.com, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06350292, orgStudyIdInfo id: 0161464, briefTitle: SLEEP-COPE: Sleep Intervention for Oppositional Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of South Florida, class: OTHER, descriptionModule briefSummary: Children with Oppositional Defiant Disorder (ODD) are at risk for insomnia, arousal dysfunction, mood problems, and noncompliance. Cognitive behavioral treatment for insomnia (CBT-I) holds promise for improving insomnia and related concerns. Telehealth delivery will reduce the burden of in-person sessions, particularly in areas where there is low mental healthcare access. Telehealth CBT-I is efficacious in adults and children but has not been tested in children with ODD. The proposed trial is the next logical step - development and iterative testing of SLEEP-COPE, a brief dyadic telehealth CBT-I for children with ODD and their parents., conditionsModule conditions: Insomnia Chronic, conditions: Oppositional Defiant Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: SLEEP: COPE, outcomesModule primaryOutcomes measure: Child Daily Sleep Diaries, primaryOutcomes measure: Parent Daily Sleep Diaries, secondaryOutcomes measure: Child Actigraphy, secondaryOutcomes measure: Parent Actigraphy, secondaryOutcomes measure: Child Salivary Cortisol, secondaryOutcomes measure: Child Hair Cortisol, secondaryOutcomes measure: The Revised Childhood Anxiety and Depression Scale, secondaryOutcomes measure: PROMIS Child Sleep Disturbance, secondaryOutcomes measure: Alabama Parenting Questionnaire, secondaryOutcomes measure: Perceived Stress Scale, secondaryOutcomes measure: Child Disruptive Behavior Disorders Checklist, secondaryOutcomes measure: Beck Depression Inventory-II, secondaryOutcomes measure: State-Trait Anxiety Inventory, secondaryOutcomes measure: PROMIS Adult Sleep Disturbance, secondaryOutcomes measure: Pediatric Sleep Questionnaire, secondaryOutcomes measure: Epworth Sleepiness Scale, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06350279, orgStudyIdInfo id: HSK39297-101, briefTitle: A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-25, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Haisco Pharmaceutical Group Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a Phase I, randomized, subject-blinded, placebo controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD),and food effect (FE) of HSK39297 following (1) a single ascending dose (part 1), (2) 10 days of multiple ascending dose (part 2), and (3) a single dose two-period crossover FE cohort., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 96, type: ESTIMATED, armsInterventionsModule interventions name: HSK39297, outcomesModule primaryOutcomes measure: The number and severity of treatment emergent adverse events (TEAEs) ., secondaryOutcomes measure: AUC, secondaryOutcomes measure: Cmax, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: t1/2, secondaryOutcomes measure: AP change, secondaryOutcomes measure: Bb, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Beijing Tongren Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Laichun Lu, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False